Abstract
There has been contradictory evidence as to whether BRCA1 associated breast cancers have a poorer prognosis than non-BRCA1 cancers. In this issue of Breast Cancer Research Robson and colleagues provide further evidence for poorer survival in BRCA1 carriers and show that it could be attributed to failure to treat small node-negative grade 3 breast cancers with chemotherapy. There still remains little evidence for a survival difference for BRCA2 related breast cancers. Although the high contralateral breast cancer risk is confirmed by this study there is no real evidence for an increase in ipsilateral recurrence or new primary breast cancers in mutation carriers up to the 10-year point.
Original language | English |
---|---|
Article number | E7 |
Journal | Breast Cancer Research |
Volume | 6 |
Issue number | 1 |
DOIs |
|
Publication status | Published - 25 Nov 2003 |
Keywords
- BRCA1
- BRCA2
- Breast cancer
- Ipsilateral
- Survival